A new treatment for advanced melanoma which has seen significant media attention is now available in Australia. MSD announced that its anti-PD1 immunotherapy KEYTRUDA (pembrolizumab) has been registered by the TGA for the treatment of the most deadly form of skin cancer – advanced melanoma. The treatment has been the subject of a Change.org petition
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.